Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Hosszuheteny – page 30

538 clinical trials in Hosszuheteny, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Hosszuheteny at a glance
538
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

538 trials in Hosszuheteny

Open in trial search

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

IgA nephropathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Primary IgA Nephropathy

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Acromegaly

Not recruiting

Study on the Long-Term Safety and Efficacy of Paltusotine for Patients with Acromegaly

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Paltusotine
  • Sponsor:Crinetics Pharmaceuticals Inc.

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Study Comparing the Effectiveness and Safety of Macitentan 75 mg and 10 mg for Patients with Pulmonary Arterial Hypertension

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Macitentan
  • Sponsor:Actelion Pharmaceuticals Ltd.

Study of Atezolizumab and Tiragolumab for Patients with Recurrent or Metastatic PD-L1 Positive Head and Neck Squamous Cell Carcinoma

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Acute kidney injury

Not recruiting

Study on TIN816 for Preventing Acute Kidney Injury in Adults Undergoing Cardiac Surgery

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:TIN816
  • Sponsor:Novartis Pharma AG

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Patients with Fistulizing Perianal Crohn's Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen - Cilag International

Study Comparing Epcoritamab and Lenalidomide with a Drug Combination for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative

Not recruiting

Study on the Long-Term Safety and Effectiveness of Ozanimod for Adults with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ozanimod
  • Sponsor:Celgene International II S.a.r.l.

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Hosszuheteny

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking clinical trials focusing on atherosclerotic cardiovascular disease prevention are currently underway. These studies aim to evaluate innovative therapeutic approaches for reducing major adverse cardiovascular events in high-risk patients.

  • Primary Prevention Studies
  • Cardiovascular Risk Management
  • Novel Therapeutic Interventions

The research specifically targets patients requiring preventive care for ASCVD, investigating treatments that could significantly impact cardiovascular mortality and morbidity rates.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.